Evidence map›Paper›PMID 35735423›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.

Matthew S Ernst, John T Lysack, Martin D Hyrcza, Shamir P Chandarana, Desiree Hao

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Biomedical reports · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Matthew S ErnstTom Baker Cancer Center, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N2, Canada.ORCID 0000-0001-7480-2223
John T LysackDivision of Head and Neck Imaging, Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.ORCID 0000-0002-6047-7965
Martin D HyrczaDepartment of Pathology and Laboratory Medicine, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 2T9, Canada.
Shamir P ChandaranaSection of Otolaryngology, Department of Surgery, University of Calgary, Calgary, AB T2N 2T9, Canada.
Desiree HaoTom Baker Cancer Center, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N2, Canada.ORCID 0000-0003-1727-1205
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC),

Indexed as

CarcinomaIndazolesBenzamidesBreast NeoplasmsGene FusionHumansBenzamidesentrectinibIndazolesentrectiniblarotrectinibmolecular testingNTRKsecretory carcinomatargeted therapy

Identifiers

PMID35735423
PMCPMC9222047
OpenAlexW4282007417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.